Vectura Group PLC (LON:VEC) has been assigned an average rating of “Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is GBX 128.50 ($1.68).
VEC has been the topic of several research analyst reports. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 140 ($1.83) price target on shares of Vectura Group in a report on Tuesday, August 21st. Peel Hunt restated a “hold” rating on shares of Vectura Group in a report on Tuesday, September 4th. Shore Capital restated a “hold” rating on shares of Vectura Group in a report on Thursday, November 8th. Numis Securities restated a “buy” rating on shares of Vectura Group in a report on Thursday, August 23rd. Finally, Royal Bank of Canada lowered their price target on shares of Vectura Group from GBX 92 ($1.20) to GBX 88 ($1.15) and set a “sector performer” rating on the stock in a report on Wednesday, September 12th.
Shares of Vectura Group stock traded down GBX 0.50 ($0.01) on Friday, hitting GBX 77.60 ($1.01). 386,740 shares of the company traded hands, compared to its average volume of 4,610,000. Vectura Group has a 12-month low of GBX 70 ($0.91) and a 12-month high of GBX 166.97 ($2.18).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Read More: Understanding the different types of bonds
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.